Radiopharm Theranostics Limited (RAD) is a clinical-stage radiotherapeutics company focused on developing and commercialising a comprehensive platform of radiopharmaceutical products. These products are designed for both therapeutic and diagnostic applications, specifically within the field of precision oncology. Their innovative approach aims to enhance the accuracy and effectiveness of cancer diagnosis and treatment, offering new possibilities for personalised patient care. Through ongoing research and development, Radiopharm Theranostics is committed to advancing the field of radiopharmaceuticals to improve outcomes for cancer patients.